Inositol vs Metformin for PCOS: Head-to-Head on Ovulation, Weight and Side Effects

Inositol vs metformin: the size of the evidence, not just the direction

Metformin’s PCOS evidence runs to a Cochrane review of 41 trials and 4,552 women; inositol’s core meta-analysis covers 9 trials and 496 women total. That gap matters as much as any single result below: the Cochrane review behind metformin’s ovulation data is an order of magnitude larger than the meta-analysis behind myo-inositol’s metabolic data. Metformin is a licensed medicine that has been studied, monitored and regulated as a drug for decades. Myo-inositol is sold as a dietary supplement, with no prescription requirement and a far lighter testing bar before it reaches a shelf — no regulator checks that a given bottle actually contains what the label claims, at the ratio it claims, before it goes on sale. Every comparison that follows sits on top of that asymmetry: more trials and tighter manufacturing oversight on one side, easier access and a milder reported side-effect profile on the other. This comparison assumes you already know what inositol is and its standard dose — start there first if you don’t.

Ovulation and cycle regularity: what the trials actually show

Myo-inositol combined with D-chiro-inositol produced 14.7 times higher odds of improved menstrual frequency than metformin alone, in a network meta-analysis of 22 trials and 1,079 women with PCOS (odds ratio 14.70, 95% CI 2.31–93.58). That is the closest thing to a direct, head-to-head number this comparison has. Against placebo alone, metformin roughly doubles to nearly quadruples the odds of ovulation (OR 2.64, 95% CI 1.85–3.75, across 41 trials), and the myo-inositol trials feeding the 2017 meta-analysis moved the same hormonal markers tied to ovulation, though ovulation rate itself is reported less consistently across those trials than it is for metformin.

Insulin resistance and metabolic markers: which moves more

HOMA-IR, the standard insulin-resistance marker, fell further on combined myo- and D-chiro-inositol than on metformin alone by 0.72 to 0.89 points, depending on the specific comparison, in the same network meta-analysis. Against placebo separately, metformin lowered HOMA-IR by an average of 0.50 points and myo-inositol lowered fasting insulin and HOMA-IR by a standardised mean difference of roughly 0.6 to 1.0 — different statistical measures that are not directly interchangeable, but both point the same direction: real, moderate improvement, not a dramatic one, from either option.

Side effects: gut symptoms versus a thinner safety record

Gastrointestinal side effects — nausea, cramping, diarrhoea — affect 22% to 40% of people on metformin, roughly four times the rate seen on placebo, according to the Cochrane review behind the international guideline. None of the primary myo-inositol trials referenced in this comparison reported a comparable adverse-event rate, and the 2024 trial that combined the two found a low, similar rate of mild adverse events in both the combination arm and the metformin-only arm — evidence that adding inositol on top of metformin did not make tolerability worse. That is a real advantage for inositol on paper, but it also reflects how much less side-effect data exists for it, not necessarily a smaller true risk.

Cost and prescription status: one you can walk in and buy, one you can’t

Generic metformin is inexpensive where it is available on a prescription — often under $15 a month in the US at standard retail or discount-program pricing — but it requires a prescriber’s sign-off, a pharmacy visit, and periodic blood work, including the kidney-function and B12 checks a prescriber uses to monitor long-term use safely. A 40:1-ratio myo-inositol supplement typically costs more per month at retail, varies significantly by brand, and requires no prescription at all — but that same lack of a prescriber also means nobody is routinely checking your progress against a specific marker, unless you arrange the bloodwork yourself. Check current pricing directly, since both figures move with formulation, dose and where you buy.

Pregnancy: what’s actually settled, and what isn’t

Metformin has been used through pregnancy in PCOS-related studies under specialist supervision for years, most visibly in trials that also tested it for infertility. Myo-inositol’s pregnancy safety data is newer, smaller in volume, and mostly exploratory rather than the large, long-running body of evidence metformin has. Neither fact in this paragraph is a recommendation to start, stop, or continue either one during pregnancy — that decision depends on why you were taking it, how far along you are, and what your prescriber is actually monitoring.

Which does the guideline actually recommend first, and why the answer changes by goal

Neither metformin nor inositol is the international guideline’s first choice for inducing ovulation — that role goes to letrozole, after a trial found live birth occurred in just 7.2% of women on metformin alone, versus 22.5% on clomiphene and 26.8% on the combination (Legro 2007, N=626), a result that helped settle letrozole as the 2023 guideline’s first-line ovulation-induction drug instead of either option on this page. Where metformin does have a defined role is metabolic management — insulin resistance, weight-adjacent metabolic markers, and as an add-on when fertility drugs alone haven’t worked. Inositol sits a level below that in the guideline’s evidence grading: often reasonable to try because of its safety profile and lack of prescription barrier, but resting on a smaller, lower-certainty trial base than metformin’s.

That is the honest shape of “which is better”: if the goal is a fast, guideline-backed path to ovulation, neither is the answer — talk to a prescriber about letrozole. If the goal is a first, lower-barrier step for metabolic markers while you sort out a longer-term plan, inositol’s safety profile and OTC access make it a reasonable starting point for many people. If the goal is maximum trial-proven insulin and lipid improvement with a licensed medicine, metformin has the larger and older evidence base behind it.

None of this means the two are interchangeable stand-ins for each other. Metformin’s guideline weight comes specifically from its metabolic and, to a lesser extent, ovulation-adjacent evidence — not from any claim that it is a fertility drug in its own right. Inositol’s appeal is less about outperforming metformin on any single hard endpoint and more about offering a comparable direction of metabolic benefit without a prescription, a titration schedule, or the gastrointestinal adjustment period metformin usually requires in its first few weeks.

Can you take inositol with metformin together?

Yes. Nothing in the trials reviewed here found a pharmacological conflict between the two — they act on insulin sensitivity through different routes, and a 2024 phase III randomised trial of 196 women specifically tested a metformin-plus-myo-inositol combination against metformin alone for 24 weeks. The combination produced a significantly greater improvement in HOMA-IR (75% of patients improved versus 60.7% on metformin alone, P=0.049) and in menstrual regularity, with a low and comparable rate of mild adverse events in both groups. That is one trial, not a settled standard of care, but it directly answers whether combining the two is dangerous or redundant: in this trial, it was neither.

Who metformin is wrong for, and who inositol is wrong for

Metformin is the wrong first step if you cannot tolerate its gastrointestinal side effects even at a slow-titrated dose, if your kidney function is significantly reduced, or if fast ovulation induction is the actual goal — that role belongs to letrozole, not metformin, per the guideline above. Metformin’s full side-effect and eligibility picture is covered in more detail separately if you are weighing it specifically.

Inositol is the wrong choice if you need a guideline-graded, high-certainty intervention and are not willing to accept a thinner evidence base in exchange for an easier route to access it, or if you’ve already tried it and it hasn’t moved your numbers after a full 24-week trial at the correct 40:1 ratio — at that point, a different mechanism such as metformin, or a different insulin-sensitising supplement like berberine, is the more useful next question.

You may see PCOS increasingly written as polyendocrine metabolic ovarian syndrome (PMOS), after a May 2026 global consensus renamed the condition. Neither drug’s evidence, dosing, or mechanism changed with the new name.

Your next step

Write down the one outcome you actually want to change — cycle regularity, insulin markers, or ovulation on a timeline — before deciding between these two. That single answer, brought to a prescriber alongside your current medication and supplement list, does more to settle “inositol or metformin” than any trial number on this page can on its own. And if neither is the right fit once you’ve worked through this, the rest of the supplements and medications section covers the other options.